VF5.F ONDINE BIOMEDICAL INC.CDI
- Market cap
- EUR 54.9M
- P/E
- -
- P/B
- 20.67x
- ROE
- -847.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is VF5.F undervalued?
Graham numberThe Graham number of ONDINE BIOMEDICAL INC.CDI cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ONDINE BIOMEDICAL INC.CDI fundamental analysis
No fundamental analysis for ONDINE BIOMEDICAL INC.CDI yet.
ONDINE BIOMEDICAL INC.CDI stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ONDINE BIOMEDICAL INC.CDI
Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfection products for various indications, including chronic sinusitis, ventilator-ass…
Full company profileONDINE BIOMEDICAL INC.CDI financial statements
ONDINE BIOMEDICAL INC.CDI annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 2.57M | 638K | 1.20M | 2.05M | 2.65M |
| Gross Profit | 1.25M | 287K | 703K | 1.32M | 1.61M |
| Operating Income | -17.5M | -18.8M | -14.8M | -19.4M | -30.0M |
| EBITDA | - | -18.8M | -13.8M | -18.5M | -28.9M |
| Net Income | -50.1M | -19.4M | -14.4M | -19.1M | -29.5M |
| EPS | -0.26 | -0.10 | -0.06 | -0.05 | -0.06 |
| Balance Sheet | |||||
| Total Assets | 34.1M | 16.6M | 5.73M | 12.8M | 14.4M |
| Total Liabilities | 4.48M | 4.93M | 3.65M | 5.95M | 10.9M |
| Shareholders' Equity | 29.7M | 11.6M | 2.09M | 6.88M | 3.49M |
| Cash & Short-term Investments | 30.4M | 13.1M | 2.98M | 9.77M | 10.6M |
| Cash Flow | |||||
| Operating Cash Flow | -12.5M | -16.3M | -13.7M | -15.5M | -23.8M |
| Capital Expenditure | 77.0K | 311K | 177K | 10.0K | 117K |
| Free Cash Flow | -12.6M | -16.7M | -13.8M | -15.5M | -24.0M |
| Ratios | |||||
| ROE | -168.9% | -166.4% | -691.2% | -277.7% | -847.0% |
| ROA | -146.7% | -116.9% | -251.3% | -148.9% | -205.2% |
| Net Profit Margin | -1,949.6% | -3,036.4% | -1,198.0% | -932.1% | -1,115.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ONDINE BIOMEDICAL INC.CDI dividends
ONDINE BIOMEDICAL INC.CDI has not paid dividends in the last 5 fiscal years.
Who owns ONDINE BIOMEDICAL INC.CDI
- Insiders 33.46%
- Institutions 30.83%
- Public & others 35.71%
- Shares outstanding 661M
- Free float 366M
ONDINE BIOMEDICAL INC.CDI company profile
- Company name
- ONDINE BIOMEDICAL INC.CDI
- Ticker
- VF5.F
- ISIN
- CA68234M2058
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 1100 Melville Street, Vancouver, BC, Canada, V6E 4A6
- Phone
- 604 669 0555
- Website
- ondinebio.com
About ONDINE BIOMEDICAL INC.CDI
Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfection products for various indications, including chronic sinusitis, ventilator-associated pneumonia, burns and other indications. Ondine Biomedical Inc. was incorporated in 1996 and is headquartered in Vancouver, Canada.
ONDINE BIOMEDICAL INC.CDI management
7- Ms. Carolyn M. Cross C.F.A., M.B.A.Founder, CEO & Executive Director
- Dr. Nicolas G. Loebel Ph.D.President, CTO & Executive Director
- Mr. Alan ThomasChief Financial Officer
- Mr. Michael AcheyVice President of Engineering & Operations
- Ms. Angelika VanceVice President of Corporate Communications
- Ms. Elaine Lei CPACorporate Controller & Company Secretary
- Mr. Nikita ParkevVP of Finance & Company Secretary